Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Texas To Require Warning Labels On Ephedrine Products

This article was originally published in The Tan Sheet

Executive Summary

All ephedrine-containing dietary supplements sold in Texas must bear a warning against use by those with certain health conditions or who are under 18, the Texas Board of Health concluded May 21. The required warning also addresses the possible consequences of exceeding recommended dosages.

You may also be interested in...



California Ephedrine Bill Slated For Senate Consideration Aug. 28

California legislation requiring warning labels on ephedra-containing dietary supplements passed out of the Senate Appropriations Committee Aug. 24 and is expected to go to the state Senate floor the week of Aug. 28. Assembly Bill 2294 was introduced by Assemblywoman Susan Davis (D) Feb. 24.

California Ephedrine Bill Slated For Senate Consideration Aug. 28

California legislation requiring warning labels on ephedra-containing dietary supplements passed out of the Senate Appropriations Committee Aug. 24 and is expected to go to the state Senate floor the week of Aug. 28. Assembly Bill 2294 was introduced by Assemblywoman Susan Davis (D) Feb. 24.

California Ephedrine Bill Slated For Senate Consideration Aug. 28

California legislation requiring warning labels on ephedra-containing dietary supplements passed out of the Senate Appropriations Committee Aug. 24 and is expected to go to the state Senate floor the week of Aug. 28. Assembly Bill 2294 was introduced by Assemblywoman Susan Davis (D) Feb. 24.

Related Content

Topics

UsernamePublicRestriction

Register

LL1131980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel